Repligen Corporation (RGEN) Key Statistics & Metrics

Repligen Corporation (RGEN) has an ST Score of 63.8 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on RGEN is Buy based on 24 analyst ratings. Our own ST Score grades it B (63.8/100). This is data, not investment advice — always do your own research.

Repligen Corporation (RGEN) earns a valuation grade of F, measured against Medical - Instruments & Supplies peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Repligen Corporation (RGEN) earns a growth grade of B, measured against Medical - Instruments & Supplies peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Repligen Corporation (RGEN) earns a profitability grade of B-, measured against Medical - Instruments & Supplies peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Repligen Corporation (RGEN) earns a financial strength grade of B+, measured against Medical - Instruments & Supplies peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Repligen Corporation (RGEN) is $162.43 from 24 analysts, which is -0.1% versus the recent price of $180.71.

Repligen Corporation (RGEN) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.